Avoiding High-risk Cath Lab Procedures Does Not Improve Hospital Scores
Study looked at hospital-level PCI performance with simulated risk avoidance strategies
Avoiding high-risk PCI procedures does not improve hospital scores according to a study presented at SCAI 2021. CTO procedure at Henry Ford Hospital, Detroit. Photo by Dave Fornell.
May 5, 2021 A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 meeting looked at hospital-level percutaneous coronary intervention (PCI) performance with simulated risk avoidance strategies and found this might not improve performance. Any individual hospital seeking to improve their performance, there is no guarantee that practicing systematic risk-avoidance will improve the measured quality of a PCI program, and may in fact worsen it, explained Ashwin Nathan M.D., a cardiology fellow at the Hospital of the University of Pennsylvania, who presented the study.
The University of North Carolina at Chapel Hill
FPG Distinguished Speaker Series Welcomes Dr. Charlene Wong
Frank Porter Graham Child Development Institute is pleased to welcome Dr. Charlene Wong as the fourth speaker in our 2020-2021 virtual distinguished speaker series
Fostering Resilience for Our Children: From Birth Through Adolescence
.
NC Integrated Care for Kids (NC InCK): An Innovative Model to Promote Child and Family Well-being in Central North Carolina
This presentation will describe: (1) the NC Integrated Care for Kids (NC InCK) model and its core components for improving child well-being and health and (2) how alternative payment models can be aligned with meaningful measures of child well-being in healthcare and beyond.
NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms
Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness.
The National Institutes of Health will fund a large, randomized, placebo controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial.